Gastrointestinal motility problems in patients with Parkinson's disease: Epidemiology, pathophysiology and guidelines for management

CNS Drugs

Volumn 11, Issue 6, 1999, Pages 435-448

  Pfeiffer, Ronald F ^a   Quigley, Eamonn M M ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BOTULINUM TOXIN; BROMHEXINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; GOLYTELY; LANSOPRAZOLE; LEVODOPA; METOCLOPRAMIDE; NULYTELY; OMEPRAZOLE; PMF 100; PROKINETIC AGENT; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ARTICLE; CONSTIPATION; DIETARY FIBER; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSPHAGIA; GASTROINTESTINAL MOTILITY; HUMAN; HYPERSALIVATION; PARKINSON DISEASE; PRIORITY JOURNAL; STOMACH PARESIS;

EID: 0033014922     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911060-00003     Document Type: Article

References (97)

1. 1. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817
2. 2. Romherg MH. Nervous diseases of man. London: Sydenham Society, 1853
3. 3. Charcot JM. Lectures on the diseases of the nervous system. Vol. 1. London: New Sydenham Society, 1877
4. 4. Hammond WA. A treatise on diseases of the nervous system. New York: Appleton & Co., 1871
5. 5. Gowers WR. Diseases of the nervous system. Philadelphia (PA): P Blakiston & Co., 1888
6. 6. Eadie MJ, Tyrer JH. Alimentary disorder in parkinsonism. Aust Ann Med 1965; 14: 13-22
7. 7. Edwards LL, Pfeiffer RF, Quigley EMM, et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991; 6: 151-6
8. 8. Edwards LL, Quigley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42: 726-32
9. 9. Edwards L, Quigley EMM, Hofman R, et al. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 1993; 8: 83-6
10. 10. Edwards LL, Quigley EMM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994; 89: 15-25
11. 11. Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease. Semin Neurol 1996; 16: 245-50
12. 12. Quigley EMM. Epidemiology and pathophysiology of gastrointestinal manifestations in Parkinson's disease. In: Corazziari E, editor. Neurogastroenterology. Berlin: deGruyter, 1996: 167-78
13. 13. Bateson MC, Gibberd FB, Wilson RSE. Salivary symptoms in Parkinson's disease. Arch Neurol 1973; 29: 274-5
14. 14. Eadie MJ. Gastric secretion in parkinsonism. Aust Ann Med 1963; 12: 346-50
15. 15. Korczyn AD. Autonomic nervous system dysfunction in Parkinson's disease. In: Calne DB, Comi G. Crippa D, et al., editors Parkinsonism and aging. New York (NY): Raven Press, 1989: 211-4
16. 16. Marsden CD. Gastrointestinal manifestations of movement disorders. In: Corazziari E, editor. Neurogastroenterology. Berlin: deGruyter. 1996: 161-5
17. 17. Korczyn AD, Autonomic nervous system disturbances in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, et al., editors. Parkinson's disease: anatomy, pathology and therapy (Advances in neurology, vol. 53). New York (NY): Raven Press, 1990: 463-8
18. 18. Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 1993; 11: 14-22
19. 19. Logemann JA, Blonsky ER, Boshes B. Editorial: dysphagia in parkinsonism. JAMA 1975; 231 (1): 69-70
20. 20. Bushman M, Dohmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989; 39: 1309-14
21. 21. Robbins JA. Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986; 19: 283-7
22. 22. Ali GN, Wallace KL, Schwartz R, et al. Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology, 1996; 110: 383-92
23. 23. Johnston BT, Li Q, Castell JA, et al. Swallowing and esophageal dysfunction in Parkinson's disease. Am J Gastroenterol 1995; 90: 1741-6
24. 24. Stroudley J, Walsh M, Radiological assessment of dysphagia in Parkinson's disease. Br J Radiol 1991; 64; 890-3
25. 25. Mari F, Matei M, Bartolini M, et al. Poor predictive value of clinical measures of dysphagia versus aspiration risk in parkinsonian patients [abstract]. Mov Disord 1997; 12 (Suppl. 1); 135
26. 26. Logemann J, Blonsky ER, Boshes B. Lingual control in Parkinson's disease. Trans Am Neurol Assoc 1973; 98: 276-8
27. 27. Blonsky ER, Logemann JA, Boshes B, et al. Comparison of speech and swallowing function in patients wilh tremor disorders and in normal geriatric patients: a cinefluorographic study. J Gerontol 1975; 30: 299-303
28. 28. Silbiger ML, Pikielny R, Donner MW. Neuromuscular disorders affecting the pharynx. Cineradiographic analysis. Invest Radiol 1967; 2: 442-8
29. 29. Byrne KG, Pfeiffer RF, Quigley EMM. Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center. J Clin Gastroenterol 1994; 19: 11-6
30. 30. Groher ME. Dysphagic patients with progressive neurologic disease. Semin Neurol 1996; 16: 355-63
31. 31. Logeman JA. Screening, diagnosis and management of neurogenic dysphagia. Semin Neurol 1996; 16: 319-27
32. 32. Penner A, Druckerman LJ. Segmentat spasms of the esophagus and their relation to parkinsonism. Am J Dig Dis 1942; 9: 282-6
33. 33. Bramble MG, Cunliffe J, Dellipam AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. J Neurol Neurosurg Psychiat 1978; 41: 709-12
34. 34. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-45
35. 35. Calne DB, Shaw DG, Spiers ASD, et al. Swallowing in parkinsonism. Br J Radiol 1970; 43: 456-7
36. 36. Paulson GR, Talrate RH. Some minor aspects of parkinsonism, especially pulmonary function. Neurology 1970; 20: 14-7
37. 37. Nowack WJ, Hatelid JM, Sohn KS, Dysphagia in parkinsonism [letter]. Arch Neurol 1977; 34: 320
38. 38. Lieberman AN, Horowitz L, Redmond P, et al. Dysphagia in Parkinson's disease. Am J Gastroenterol 1980; 74: 157-60
39. 39. Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989; 4: 47-52
40. 40. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996; 11: 729-32
41. 41. Qualman SJ, Haupt HM, Yang P, et al. Oesophageal Lewy bodies associated with ganglion cell loss in achalasia. Gastroenterology 1984; 87: 848-56
42. 42. Born LJ, Harned RH, Rikkers LF, et al. Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11: 53-8
43. 43. Palmer ED. Dysphagia in parkinsonism. JAMA 1974; 229 (10): 1349
44. 44. Camilleri M, Bharucha AE. Gastrointestinal dysfunction in neurologic disease. Semin Neurol 1996; 16: 203-16
45. 45. Sulla M, Hardoff R, Giladi N, et al. Gastric emptying time and gastric motilily in patients with untreated Parkinson's disease [abstract]. Mov Disord 1996; 11 Suppl. 1: 167
46. 46. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996; 46: 1051-4
47. 47. Wade DN, Mearrick PT, Morris J. Active transport of I-dopa in the intestine. Nature 1973; 242: 463-5
48. 48. Sasahara K, Nitanai J, Habara T, et al. Dosage from design for improvement of bioavailability of levodopa: absorption and metabolism of levodopa in intestinal segment of dogs. J Pharm Sci 1981; 70: 1157-60
49. 49. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35-50
50. 50. Evans MA, Broe GA, Triggs EJ, et al. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 1981; 31: 1288-94
51. 51. Valenzuala JE. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology 1976; 71: 1019-22
52. 52. Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980; 27: 414-20
53. 53. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology 1988; 38: 419-21
54. 54. Syed N, Murphy J, Zimmerman Jr T, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13: 336-8
55. 55. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996; 39: 400-4
56. 56. Vaamonde J, Luquin MR, Obeso J. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 1991; 114: 604-17
57. 57. Stibe CM, Lees AJ, Kempster PA, et at. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1:403-6
58. 58. Kleedorfer B, Turjanski N, Ryan R, et al. Intranasal apomorphine in Parkinson's disease. Neurology 1991; 41: 761-2
59. 59. Montrastruc JL, Rascol O, Senard JM, et al. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991; 14: 432-7
60. 60. van Laar T, Jansen ENH, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10: 433-9
61. 61. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-70
62. 62. Mouradian MM, Chase TN. Improved dopaminergic therapy of Parkinson's disease. In: Mursden CD, Fahn S, editors. Movement Disorders 3. Oxford: Butterworth-Heinemann 1994: 180-9
63. 63. Calabrese VP, Vaughan J, Lucas J, et al. N-0923, a tnansdermal amino tetralin D2 dopamine agonist in the treatment of Parkinson's disease [abstract]. Neurology 1997; 48 Suppl. 2: A270
64. 64. Wiseman LR, Faulds D, Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52
65. 65. Djaldetti R, Koren M, Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995; 10: 81-4
66. 66. Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 952-7
67. 67. Farrugia G, Camilleri M, Whitehead WE. Therapeutic strategies for motility disorders. Medications, nutrition, biofeedback, and hypnotherapy. Gastroenterol Clin 1996; 25: 225-46
68. 68. Ashraf W, Park F, Lof J, et al. An examination of reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996; 91: 26-32
69. 69. Schwab RS, England AC. Parkinson's disease. J Chronic Dis 1958; 8: 488-509
70. 70. Pallis CA. Parkinsonism: natural history and clinical features. Br Med J 1971; 3: 683-90
71. 71. Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klin Wochenschr 1991; 69: 906-9
72. 72. Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946-51
73. 73. Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37: 1253-5
74. 74. Wakabayashi K, Takahashi E, Ohama F, et al. Parkinson's disease: an immunohistochemical study of Lewy-body containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581-3
75. 75. Wakabayashi K, Takahashi H, Ohama E, et al. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. In: Narabayashi H, Nagutsu T, Yanagisawa N, et al., editors. Parkinson's disease. From basic research to treatment (Advances in neurology vol. 60). New York (NY); Raven Press, 1993; 609-12
76. 76. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346; 861-4
77. 77. Lewitan A, Nathanson L, Slade WR Jr. Megacolon and dilatation of the small howel in parkinsonism. Gastroenterology 1952; 17: 367-74
78. 78. Caplan LH, Jacobson HG, Rubinstein BM, et al. Megacolon and volvulus in Parkinson's disease. Radiology 1965; 85: 73-8
79. 79. Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc 1987; 35: 683-4
80. 80. Bak MP, Boley SJ. Sigmoid volvulus in elderly patients. Am J Surg 1986; 151: 71-5
81. 81. Coruzziari E, Badiali D. Management of lower gastrointestinal tract dysfunction. Semin Neurol 1996; 16: 289-96
82. 82. Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson's disease. Clin Neuropharmacol 1992; 15: 375-80
83. 83. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996; 41: 1636-42
84. 84. Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord 1993; 8: 339-43
85. 85. Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease. Mov Disord 1997; 12: 423-5
86. 86. Sempere AP, Duarte J, Cabezas C, et al. Aggravation of parkinsonian tremor by cisapride. Clin Neuropharmacol 1995; 18: 76-8
87. 87. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease [letter]. JAMA 1983; 249: 1148
88. 88. Madoff RD, Williams JG, Caushaj PF. Fecal incontinence. N Engl J Med 1992; 326: 1 1002-7
89. 89. Parks AG. Anorectal incontinence. Proc R Soc Med 1975; 68: 681-90
90. 90. Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatr 1988; 51: 1503-7
91. 91. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989; 46: 1061-4
92. 92. Ashraf W, Wszolek ZK, Pfeiffer RF, et al. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995; 10: 650-7
93. 93. Stocchi F, Vacca L, D'Alba L, et al. Anorectal motor function in patients with Parkinson's disease [abstract]. Mov Disord 1996; 11 Suppl. 1: 182
94. 94. Jost WH. Electromyogram of the external anal sphincter in idiopathic Parkinson's syndrome [abstract]. Mov Disord 1996; 11 Suppl. 1: 192
95. 95. Ashraf W, Pfeiffer RF, Quigley EMM. Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation. Mov Disord 1994; 9: 655-63
96. 96. Edwards LL, Quigley EMM, Harned RK, et. al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993; 33: 490-3
97. 97. Albanese A, Maria G, Bentivoglio A. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord 1997; 12: 764-6